Article
The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology - 1 Jan 2000
Tadic Ljiljana, Marjanovic Goran, Macukanovic-Golubovic Lana, Krstic Miljan, Jevtovic-Stoimenov Tatjana, Kostov Milos, Smelcerovic Zaklina, Stojanovic Mariola
Abstract excerpt
PURPOSE: Immunochemotherapy used in the treatment of non-Hodgkin diffuse large B-cell lymphoma (DLBCL) modifies the course of disease and has a positive effect on overall survival (OS). The purpose of this study was to verify the existence of the important Myd 88 mutation and other immunohistochemical factors on disease prognosis in patients with DLBCL in southeast Serbia. METHODS: Immunohistochemical expression...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.